INAB vs. SGTX, TTOO, HCWB, ORPH, ENLV, IVVD, SCLX, ELEV, CRBU, and GLUE
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Sigilon Therapeutics (SGTX), T2 Biosystems (TTOO), HCW Biologics (HCWB), Orphazyme A/S (ORPH), Enlivex Therapeutics (ENLV), Invivyd (IVVD), Scilex (SCLX), Elevation Oncology (ELEV), Caribou Biosciences (CRBU), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "medical" sector.
Sigilon Therapeutics (NASDAQ:SGTX) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
Sigilon Therapeutics presently has a consensus target price of $21.00, indicating a potential downside of 6.54%. IN8bio has a consensus target price of $10.00, indicating a potential upside of 592.04%. Given Sigilon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Sigilon Therapeutics.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -171.29%. IN8bio's return on equity of -83.07% beat Sigilon Therapeutics' return on equity.
Sigilon Therapeutics received 3 more outperform votes than IN8bio when rated by MarketBeat users. However, 70.00% of users gave IN8bio an outperform vote while only 58.54% of users gave Sigilon Therapeutics an outperform vote.
92.1% of IN8bio shares are owned by institutional investors. 6.5% of Sigilon Therapeutics shares are owned by company insiders. Comparatively, 15.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Sigilon Therapeutics has a beta of 4.12, indicating that its share price is 312% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.
IN8bio has lower revenue, but higher earnings than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, IN8bio had 3 more articles in the media than Sigilon Therapeutics. MarketBeat recorded 3 mentions for IN8bio and 0 mentions for Sigilon Therapeutics. Sigilon Therapeutics' average media sentiment score of 0.15 beat IN8bio's score of 0.00 indicating that IN8bio is being referred to more favorably in the news media.
Summary
IN8bio beats Sigilon Therapeutics on 12 of the 17 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
